Data sourced from ClinicalTrials.gov (NIH registry) Updated weekly IRB-supervised studies only

Home/MI/Muskegon

Updated October 2026 from ClinicalTrials.gov

Paid Clinical Trials in Muskegon, MI

Studies commonly pay $75 to $4,500 per completed study

62 clinical trials are currently recruiting participants within 30 miles of Muskegon. Listings below come straight from the official NIH registry, alongside the area's top-rated research centers with real Google reviews.

62studies recruiting

3+research centers nearby

4condition categories

Live from the NIH registry

Studies recruiting near Muskegon right now

Top 25 of 62 recruiting studies, sorted by proximity — each links to its official registry page

Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer

Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8 Phase 3 Interventional 3,680 participants sought

Trinity Health Muskegon Hospital — Muskegon, Michigan (0.6 mi) · Sponsor: National Cancer Institute (NCI)

See eligibility & contact on ClinicalTrials.gov (NCT06058377)

Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma

Endometrial Adenocarcinoma, Endometrial Clear Cell Adenocarcinoma Phase 2 Interventional 81 participants sought

Trinity Health Muskegon Hospital — Muskegon, Michigan (0.6 mi) · Sponsor: National Cancer Institute (NCI)

See eligibility & contact on ClinicalTrials.gov (NCT05112601)

Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])

Lung Non-Small Cell Carcinoma, Lung Non-Small Cell Squamous Carcinoma Phase 3 Interventional 1,210 participants sought

Trinity Health Muskegon Hospital — Muskegon, Michigan (0.6 mi) · Sponsor: National Cancer Institute (NCI)

See eligibility & contact on ClinicalTrials.gov (NCT04267848)

Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy After Surgical Removal of the Bladder, Kidney, Ureter, and Urethra for Urothelial Cancer Treatment, MODERN Study

Muscle Invasive Bladder Urothelial Carcinoma, Muscle Invasive Renal Pelvis Urothelial Carcinoma Phase 2, Phase 3 Interventional 992 participants sought

Trinity Health Muskegon Hospital — Muskegon, Michigan (0.6 mi) · Sponsor: National Cancer Institute (NCI)

See eligibility & contact on ClinicalTrials.gov (NCT05987241)

Lanreotide Versus Placebo Before Surgery to Prevent a Surgical Complication Called a Pancreatic Fistula

Pancreatic Carcinoma, Pancreatic Neoplasm Phase 3 Interventional 274 participants sought

Trinity Health Muskegon Hospital — Muskegon, Michigan (0.6 mi) · Sponsor: SWOG Cancer Research Network

See eligibility & contact on ClinicalTrials.gov (NCT06807437)

Testing the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma

Endometrial Carcinoma, Endometrial Clear Cell Adenocarcinoma Phase 3 Interventional 360 participants sought

Trinity Health Muskegon Hospital — Muskegon, Michigan (0.6 mi) · Sponsor: National Cancer Institute (NCI)

See eligibility & contact on ClinicalTrials.gov (NCT05256225)

Testing the Addition of the Anti-Cancer Drug Tivozanib to Immunotherapy (Pembrolizumab) After Surgery to Remove All Known Sites of Kidney Cancer

Clear Cell Renal Cell Carcinoma, Renal Cell Carcinoma (RCC) Phase 3 Interventional 1,040 participants sought

Trinity Health Muskegon Hospital — Muskegon, Michigan (0.6 mi) · Sponsor: Alliance for Clinical Trials in Oncology

See eligibility & contact on ClinicalTrials.gov (NCT06661720)

Studying Chemotherapy With or Without Panitumumab for Unresectable, Locally Advanced, or Metastatic Pancreatic Cancer Without KRAS Mutations

Locally Advanced Pancreatic Adenocarcinoma, Metastatic Pancreatic Adenocarcinoma Phase 3 Interventional 94 participants sought

Trinity Health Muskegon Hospital — Muskegon, Michigan (0.6 mi) · Sponsor: SWOG Cancer Research Network

See eligibility & contact on ClinicalTrials.gov (NCT06998940)

BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study

Multiple conditions Phase 2 Interventional 150 participants sought

Trinity Health Muskegon Hospital — Muskegon, Michigan (0.6 mi) · Sponsor: National Cancer Institute (NCI)

See eligibility & contact on ClinicalTrials.gov (NCT05136196)

Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial

Advanced Malignant Solid Neoplasm, Anatomic Stage III Breast Cancer AJCC v8 Phase 2 Interventional 2,900 participants sought

Trinity Health Muskegon Hospital — Muskegon, Michigan (0.6 mi) · Sponsor: National Cancer Institute (NCI)

See eligibility & contact on ClinicalTrials.gov (NCT05564377)

Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early-Stage Triple Negative Breast Cancer

Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8 Phase 3 Interventional 2,400 participants sought

Trinity Health Muskegon Hospital — Muskegon, Michigan (0.6 mi) · Sponsor: SWOG Cancer Research Network

See eligibility & contact on ClinicalTrials.gov (NCT05929768)

Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients With Progressive Meningiomas

Intracranial Meningioma, Recurrent Meningioma Phase 2 Interventional 124 participants sought

Trinity Health Muskegon Hospital — Muskegon, Michigan (0.6 mi) · Sponsor: Alliance for Clinical Trials in Oncology

See eligibility & contact on ClinicalTrials.gov (NCT02523014)

Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics

Breast Carcinoma, Colorectal Carcinoma N/A Observational 2,000 participants sought

Trinity Health Muskegon Hospital — Muskegon, Michigan (0.6 mi) · Sponsor: Wake Forest University Health Sciences

See eligibility & contact on ClinicalTrials.gov (NCT06418204)

Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma (NDMM) When a Stem Cell Transplant is Not a Medically Suitable Treatment

Plasma Cell Myeloma Phase 3 Interventional 510 participants sought

Trinity Health Muskegon Hospital — Muskegon, Michigan (0.6 mi) · Sponsor: SWOG Cancer Research Network

See eligibility & contact on ClinicalTrials.gov (NCT05561387)

Cost Communication and Financial Navigation in Cancer Patients (COSTCOM)

Malignant Solid Neoplasm N/A Interventional 760 participants sought

Trinity Health Muskegon Hospital — Muskegon, Michigan (0.6 mi) · Sponsor: ECOG-ACRIN Cancer Research Group

See eligibility & contact on ClinicalTrials.gov (NCT06295367)

S1703 Serum Tumor Marker Directed Disease Monitoring in Patients With Hormone Receptor Positive Her2 Negative Metastatic Breast Cancer

Anatomic Stage IV Breast Cancer AJCC v8, Estrogen Receptor Positive N/A Interventional 739 participants sought

Trinity Health Muskegon Hospital — Muskegon, Michigan (0.6 mi) · Sponsor: SWOG Cancer Research Network

See eligibility & contact on ClinicalTrials.gov (NCT03723928)

Evaluating the Impact of Social and Genetic Factors on Outcomes in Adolescent and Young Adult Cancer Survivors

Hodgkin Lymphoma, Non-Hodgkin Lymphoma N/A Observational 2,000 participants sought

Trinity Health Muskegon Hospital — Muskegon, Michigan (0.6 mi) · Sponsor: ECOG-ACRIN Cancer Research Group

See eligibility & contact on ClinicalTrials.gov (NCT06002828)

De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)

Stage I Breast Cancer Phase 3 Interventional 1,670 participants sought

Trinity Health Muskegon Hospital — Muskegon, Michigan (0.6 mi) · Sponsor: NRG Oncology

See eligibility & contact on ClinicalTrials.gov (NCT04852887)

Collection and Storage of Tissue and Blood Samples From Patients With Cancer

Hematopoietic and Lymphatic System Neoplasm, Malignant Solid Neoplasm N/A Observational 5,000 participants sought

Trinity Health Muskegon Hospital — Muskegon, Michigan (0.6 mi) · Sponsor: National Cancer Institute LAO

See eligibility & contact on ClinicalTrials.gov (NCT02474160)

A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab

Lugano Classification Limited Stage Hodgkin Lymphoma AJCC v8 Phase 3 Interventional 1,875 participants sought

Trinity Health Muskegon Hospital — Muskegon, Michigan (0.6 mi) · Sponsor: National Cancer Institute (NCI)

See eligibility & contact on ClinicalTrials.gov (NCT05675410)

A Study to Compare the Administration of Encorafenib + Binimetinib + Nivolumab Versus Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma With Brain Metastases

Acral Lentiginous Melanoma, Clinical Stage IV Cutaneous Melanoma AJCC v8 Phase 2 Interventional 112 participants sought

Trinity Health Muskegon Hospital — Muskegon, Michigan (0.6 mi) · Sponsor: SWOG Cancer Research Network

See eligibility & contact on ClinicalTrials.gov (NCT04511013)

S1501 Dual Observational and Randomized Cohort Study of Patients With Metastatic HER-2+ Breast Cancer at Risk of Cardiac Toxicity

Cardiotoxicity, HER2/Neu Positive Phase 3 Interventional 491 participants sought

Trinity Health Muskegon Hospital — Muskegon, Michigan (0.6 mi) · Sponsor: SWOG Cancer Research Network

See eligibility & contact on ClinicalTrials.gov (NCT03418961)

Five or Ten Year Colonoscopy for 1-2 Non-Advanced Adenomatous Polyps

Adenocarcinoma of the Colon, Adenocarcinoma of the Rectum N/A Interventional 9,500 participants sought

Trinity Health Muskegon Hospital — Muskegon, Michigan (0.6 mi) · Sponsor: NRG Oncology

See eligibility & contact on ClinicalTrials.gov (NCT05080673)

Evaluating the Addition of the Immunotherapy Drug Atezolizumab to Standard Chemotherapy Treatment for Advanced or Metastatic Neuroendocrine Carcinomas That Originate Outside the Lung

Advanced Extrapulmonary Neuroendocrine Carcinoma, Metastatic Extrapulmonary Neuroendocrine Carcinoma Phase 2, Phase 3 Interventional 189 participants sought

Trinity Health Muskegon Hospital — Muskegon, Michigan (0.6 mi) · Sponsor: National Cancer Institute (NCI)

See eligibility & contact on ClinicalTrials.gov (NCT05058651)

Comparing the Effectiveness of Less Invasive Procedures With the Current Standard of Care for the Treatment of Older Adults With Early-Stage Melanoma

Cutaneous Melanoma Phase 3 Interventional 428 participants sought

Trinity Health Muskegon Hospital — Muskegon, Michigan (0.6 mi) · Sponsor: ECOG-ACRIN Cancer Research Group

See eligibility & contact on ClinicalTrials.gov (NCT07068074)

Actively enrolling

Studies you may be able to join near Muskegon

These studies are recruiting through partner research networks. We may be paid a referral fee if you complete their screening form — this never changes what you pay (nothing) or the compensation the study offers you.

See which clinical studies you may qualify for

A partner research network matches volunteers with studies that are currently enrolling in the United States. You answer a few screening questions about your health and where you live; if a study looks like a fit, its team contacts you to confirm eligibility.

Screening is free and takes a few minutes. Eligibility and any compensation are confirmed by the study team, not by this site.

Check your eligibility

Google-rated

Top-rated research centers in Muskegon

Dedicated clinical research sites near you — with their real Google ratings, reviews and contact details

West Michigan Clinical Research Center

2093 Health Dr SW Ste 201, Wyoming, MI 49519

(616) 328-5344

Website

Center for Clinical Research at WMed

★ 5.0 (1 reviews)

1000 Oakland Dr, Kalamazoo, MI 49008

(269) 337-4264

"I would like overnight clinic study paid. Kalamazoo"

— Terri Dee Little, 5★

The Cancer & Hematology Centers

★ 4.8 (368 reviews)

6425 Harvey St, Norton Shores, MI 49444

(231) 737-3469

Website

"When you get checked in for your appointment make sure that if you pay you get a receipt. There was only 1 month I did not pay because of a lost car…"

— Rebecca Provatas, 1★

Clinical trials in Muskegon: what's recruiting

The Muskegon area currently has 62 studies open to new participants, according to the ClinicalTrials.gov registry maintained by the U.S. National Institutes of Health. Among the studies closest to Muskegon, the most active research areas are:

Cancer & Oncology23 studies
Liver & Kidney2 studies
Heart & Vascular1 studies
Lungs & Breathing1 studies

Every listing shows the study phase, the recruiting site and its distance from Muskegon, and links to the official registry page where eligibility criteria and study contacts are published. Compensation is set by each sponsor: industry surveys report typical payments of $75 to $4,500 per completed study, with short observational studies at the low end and multi-visit or overnight Phase 1 studies at the high end.

How to enroll in a paid study in Muskegon

Start with a study whose condition matches your profile — or a healthy-volunteer study if you have no diagnosis. Contact the research site through the registry page, complete a short phone screen, then attend an in-person screening visit. If you qualify, the study team walks you through the informed consent document, which details every procedure, risk and payment before you commit. You can withdraw at any point, and enrollment is always free.

Muskegon participants can also register with the dedicated research centers listed above — many maintain volunteer databases and call when a matching study opens — or sign up for our email alert below to hear when a new study starts recruiting within 30 miles of your ZIP code.

Frequently asked questions

How much do paid clinical trials in Muskegon pay?

Compensation varies by study length, procedures and overnight stays. Industry surveys report typical payments from $75 to $4,500 per completed study, with simple observational studies at the low end and multi-week inpatient Phase 1 studies at the high end. Each listing's study team will confirm the exact amount before you enroll.

Are clinical trials in Muskegon safe?

Every trial on this page is registered on ClinicalTrials.gov, the official NIH registry, and is overseen by an Institutional Review Board (IRB). Before joining you receive an informed consent document detailing procedures, risks and compensation. Participation is voluntary and you can withdraw at any time.

How do I join a study in Muskegon, MI?

Pick a study that matches your profile, contact the research site (or apply through the study links on this page), pass a phone pre-screen, then attend an in-person screening visit. If you qualify, you review and sign the informed consent and the study begins. The process typically takes 1-3 weeks.

Is compensation for clinical trials taxable?

In the U.S., clinical trial compensation is generally considered taxable income, and research sites may issue a 1099 form for payments above $600 in a year. Reimbursements for travel or meals are typically treated differently. Consult a tax professional for your situation.

Can I be in more than one clinical trial at a time?

Generally no — most studies exclude participants currently enrolled in another trial, and paid Phase 1 studies enforce a washout period (often 30 days or more) between studies. Frequent healthy volunteers in Muskegon typically complete one or two studies per year.

Paid clinical trials near Muskegon

Other metros within reach

Grand Rapids, MI463 Kalamazoo, MI102 South Bend, IN105 Elkhart, IN105 Milwaukee, WI699 Lansing, MI172 Chicago, IL2,429 Round Lake Beach, IL468

By condition

Eligibility and exclusions, condition by condition

Alcoholic Liver Disease in Muskegon Bladder Issues Due To Spinal Cord Injury in Muskegon All conditions

More of MI

South Lyon1,327 Detroit1,198 Ann Arbor1,182 Grand Rapids463 Lansing172 Flint170 Kalamazoo102

New paid studies open every week

Get an email when a new clinical trial starts recruiting within 30 miles of your ZIP code. No spam — only real studies from the NIH registry.

Get free trial alerts